Idebenone + Placebo

Phase 3Withdrawn

0 views this week 0 watching💤 Quiet

Interest: 22/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Leber's Hereditary Optic Neuropathy

Conditions

Leber's Hereditary Optic Neuropathy

Trial Timeline

— → —

NCT ID

NCT01495715

About Idebenone + Placebo

Idebenone + Placebo is a phase 3 stage product being developed by Santhera Pharmaceuticals for Leber's Hereditary Optic Neuropathy. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01495715. Target conditions include Leber's Hereditary Optic Neuropathy.

What happened to similar drugs?

1 of 1 similar drugs in Leber's Hereditary Optic Neuropathy were approved

Approved (1) Terminated (0) Active (0)

✅IdebenoneSanthera PharmaceuticalsApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01495715	Phase 3	Withdrawn	—	—	Leber's Hereditary Optic Neuropathy
NCT01303406	Phase 3	Completed	Apr 1, 2011	Jul 1, 2012	Friedreich's Ataxia
NCT00747487	Phase 2	Completed	Nov 1, 2007	Feb 1, 2010	Leber's Hereditary Optic Neuropathy
NCT00905268	Phase 3	Completed	Apr 1, 2006	Jan 1, 2010	Friedreich's Ataxia
NCT00654784	Phase 2	Completed	Oct 1, 2005	Aug 1, 2007	Duchenne Muscular Dystrophy (DMD)

Competing Products

4 competing products in Leber's Hereditary Optic Neuropathy

See all competitors

Product	Company	Stage	Hype Score
Idebenone + Placebo	Santhera Pharmaceuticals	Phase 2	25
Idebenone	Santhera Pharmaceuticals	Approved	33
Idebenone 150 MG Oral Tablet	Santhera Pharmaceuticals	Pre-clinical	16
Idebenone	Santhera Pharmaceuticals	Pre-clinical	16